BiotechTube

Azithromycin plus Chloroquine + Artemether-lumefantrine

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malaria, Falciparum

Conditions

Malaria, Falciparum

Trial Timeline

Jun 1, 2008 → Sep 1, 2010

NCT ID
NCT00677833

About Azithromycin plus Chloroquine + Artemether-lumefantrine

Azithromycin plus Chloroquine + Artemether-lumefantrine is a phase 2/3 stage product being developed by Pfizer for Malaria, Falciparum. The current trial status is completed. This product is registered under clinical trial identifier NCT00677833. Target conditions include Malaria, Falciparum.

What happened to similar drugs?

11 of 19 similar drugs in Malaria, Falciparum were approved

Approved (11) Terminated (1) Active (8)
🔄KLU156 + CoartemNovartisPhase 3
🔄Artemether-lumefantrineNovartisPhase 3
🔄Artemether-lumefantrineNovartisPhase 3
✅COA566NovartisApproved
✅Artesunate-mefloquine + Atovaquone-proguanil + Artemether-lumefantrineNovartisApproved
✅Co-artemetherNovartisApproved
🔄Sulfadoxine pyrimethamine + PyramaxNovartisPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00677833Phase 2/3Completed

Competing Products

20 competing products in Malaria, Falciparum

See all competitors
ProductCompanyStageHype Score
SAR97276ASanofiPhase 2
27
SJ733 + CobicistatEisaiPhase 1
29
(+)-SJ000557733 (SJ733)EisaiPhase 2
35
E1018 + PlaceboEisaiPhase 1
36
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
36
ZY19489 Capsule + Placebo CapsuleZydus LifesciencesPhase 1
29
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mgMerckPhase 2
35
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanilMerckPhase 1
29
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mgMerckPhase 2
35
KLU156 + CoartemNovartisPhase 3
40
KAF156NovartisPhase 2
35
KAE609 + IV Artesunate + CoartemNovartisPhase 2
35
KAE609NovartisPhase 2
35
artemether:lumefantrine (2.5 mg:30 mg)NovartisPhase 2/3
30
Artemether-lumefantrine (COA566)NovartisPhase 2/3
38
INE963NovartisPhase 2
35
Ganaplacide + ItraconazoleNovartisPhase 1
29
KAE609 + Piperaquine PhosphateNovartisPhase 1
21
Artemether-lumefantrineNovartisPhase 3
40
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35